Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

24.01 +0.70 (+3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
From Cassava Sciences, Inc.
Via GlobeNewswire
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Expansion of Leadership Team
From Cassava Sciences, Inc.
Via GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which... 
Via FinancialNewsMedia
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Cassava Sciences Announces Initiation of an Open-label Extension Study
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates 
Via MarketBeat
Exposures Product Safety
CASSAVA SCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
Cassava Sciences Responds to Media Reports
From Cassava Sciences, Inc.
Via GlobeNewswire
CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
From Kahn Swick & Foti, LLC
Via Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the... 
Via FinancialNewsMedia
Cassava Sciences, Inc. (NASDAQ:SAVA) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Cassava Sciences, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster... 
Via FinancialNewsMedia
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia... 
Via FinancialNewsMedia
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Via AB Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.